About: Stephen B Hanauer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Stephen B Hanauer Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher

Attributes	Values
rdf:type	Item
description	researcher (en) 研究者 (ja) investigador (es) araştırmacı (tr) wetenschapper (nl) дослідник (uk) эрдэмтэн (mn)
rdfs:label	Stephen B Hanauer (en) Stephen B Hanauer (nl) Stephen B. Hanauer (cs)
skos:prefLabel	Stephen B Hanauer (en) Stephen B Hanauer (nl) Stephen B. Hanauer (cs)
name	Stephen B Hanauer (en) Stephen B Hanauer (nl) Stephen B. Hanauer (cs)
given name	wds:Q87669570-765785FB-67E8-4843-B561-A28C3938E053
given name	Stephen
instance of	wds:Q87669570-76249900-2C72-44D4-AF22-E294F8DDC992
NL CR AUT ID	wds:Q87669570-C6B2D5D2-792A-4EF6-AD4B-22D605F43512
instance of	Homo sapiens
NL CR AUT ID	nlk20050163067
skos:altLabel	Stephen Hanauer (en)
occupation	wds:Q87669570-760802CB-19F3-44BC-8514-1FC490DA22AD
employer	wds:Q87669570-B6DFEF2B-109D-43B0-BC7B-DA80AC717350
sex or gender	wds:Q87669570-3EEA8D2F-4345-45C9-8A69-A09E713562C7
ISNI	wds:Q87669570-29C6397D-A6D4-4FFD-BD60-699C38E7F1EB
VIAF ID	wds:Q87669570-2AB17F7A-6CA8-4408-8515-0D74AFD6761F
IdRef ID	wds:Q87669570-e3a95e66-454b-45f4-9ccc-6dce139f8c6e
on focus list of Wikimedia project	wds:Q87669570-C7AB1D30-2C17-46B9-9824-3B5EEA978BD4
VIAF ID	http://viaf.org/viaf/55370247
IdRef ID	http://www.idref.fr/032479670/id
occupation	researcher
employer	Northwestern University
sex or gender	male
ISNI	0000000115710652
VIAF ID	55370247
IdRef ID	032479670
on focus list of Wikimedia project	WikiProject PCC Wikidata Pilot/Northwestern University Libraries
ORCID iD	wds:Q87669570-B973EB27-2758-4950-BD41-CDD16598A66A
ORCID iD	https://orcid.org/0000-0002-3268-932X
ORCID iD	0000-0002-3268-932X
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q87669570
is author of	A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease Ustekinumab induction and maintenance therapy in refractory Crohn's disease An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease AST-120 (spherical carbon adsorbent) in the treatment of perianal fistulae in mild-to-moderate Crohn's disease: FHAST-1, a phase 3, multicenter, placebo-controlled study Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States Infliximab in the treatment of Crohn's disease: a user's guide for clinicians miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis Smoking and inflammatory bowel disease Quality indicators for inflammatory bowel disease: development of process and outcome measures Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis Evidence for an inflammatory bowel disease locus on chromosome 3p26: linkage, transmission/disequilibrium and partitioning of linkage Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial AGA technical review on perianal Crohn’s disease Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease Infliximab for induction and maintenance therapy for ulcerative colitis A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease Abatacept for Crohn's disease and ulcerative colitis. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial Maintenance therapy with certolizumab pegol for Crohn's disease Treat to target: a proposed new paradigm for the management of Crohn's disease Vedolizumab as induction and maintenance therapy for ulcerative colitis Vedolizumab as induction and maintenance therapy for Crohn's disease Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed Management of Crohn's disease in adults Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Management of Crohn's disease in adults. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. Natalizumab Induction and Maintenance Therapy for Crohn's Disease Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease An evidence-based systematic review on medical therapies for inflammatory bowel disease

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software